Comment
doi: 10.1016/S2213-8587(17)30109-2.
Semaglutide, lipid-lowering drugs, and NAFLD
Affiliations
- PMID: 28434490
- DOI: 10.1016/S2213-8587(17)30109-2
Item in Clipboard
Comment
Semaglutide, lipid-lowering drugs, and NAFLD
Lancet Diabetes Endocrinol.
2017 May.
No abstract available
Comment in
-
Semaglutide, lipid-lowering drugs, and NAFLD - Author's reply.Lancet Diabetes Endocrinol. 2017 May;5(5):330. doi: 10.1016/S2213-8587(17)30110-9. Lancet Diabetes Endocrinol. 2017. PMID: 28434491 No abstract available.
Comment on
-
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.Lancet Diabetes Endocrinol. 2017 Apr;5(4):251-260. doi: 10.1016/S2213-8587(17)30013-X. Epub 2017 Jan 17. Lancet Diabetes Endocrinol. 2017. PMID: 28110911 Clinical Trial.
Similar articles
-
Semaglutide, lipid-lowering drugs, and NAFLD - Author's reply.Lancet Diabetes Endocrinol. 2017 May;5(5):330. doi: 10.1016/S2213-8587(17)30110-9. Lancet Diabetes Endocrinol. 2017. PMID: 28434491 No abstract available.
-
Semaglutide is safe and efficacious for NASH resolution.Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):6. doi: 10.1038/s41575-020-00396-z. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33257834 No abstract available.
-
Semaglutide or Placebo for Nonalcoholic Steatohepatitis.N Engl J Med. 2021 Jul 8;385(2):e6. doi: 10.1056/NEJMc2106921. N Engl J Med. 2021. PMID: 34233104 No abstract available.
-
GLP-1 receptor agonists in NAFLD.Diabetes Metab. 2017 Apr;43 Suppl 1:2S28-2S33. doi: 10.1016/S1262-3636(17)30070-8. Diabetes Metab. 2017. PMID: 28431668 Review.
-
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4. Metabolism. 2017. PMID: 28521870 Review.
Cited by
-
Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.PLoS One. 2022 Feb 22;17(2):e0261310. doi: 10.1371/journal.pone.0261310. eCollection 2022. PLoS One. 2022. PMID: 35192632 Free PMC article.
-
Current and future pharmacological therapies for NAFLD/NASH.J Gastroenterol. 2018 Mar;53(3):362-376. doi: 10.1007/s00535-017-1415-1. Epub 2017 Dec 16. J Gastroenterol. 2018. PMID: 29247356 Free PMC article. Review.
-
Tocopheryl quinone improves non-alcoholic steatohepatitis (NASH) associated dysmetabolism of glucose and lipids by upregulating the expression of glucagon-like peptide 1 (GLP-1) via restoring the balance of intestinal flora in rats.Pharm Biol. 2021 Dec;59(1):723-731. doi: 10.1080/13880209.2021.1916542. Pharm Biol. 2021. PMID: 34139927 Free PMC article.
-
Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.Pharm Res. 2022 Jun;39(6):1233-1248. doi: 10.1007/s11095-022-03302-1. Epub 2022 Jun 1. Pharm Res. 2022. PMID: 35650449 Free PMC article. Review.
-
The Discovery and Development of Liraglutide and Semaglutide.Front Endocrinol (Lausanne). 2019 Apr 12;10:155. doi: 10.3389/fendo.2019.00155. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31031702 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
